Liver-Specific Regulatory Elements for Compact Gene Therapy Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy vectors face challenges in achieving therapeutic levels of liver-specific gene expression with sufficient specificity and compactness, often compromising expression levels and/or vector efficiency due to the size and activity of promoter/enhancer sequences.
Innovation Solution
The use of nucleic acid regulatory elements of 600 nucleotides or less, such as SEQ ID NO:3, SEQ ID NO:1, SEQ ID NO:2, and others, enhance liver-specific gene expression by operably linking them to minimal promoters, allowing high and tissue-specific expression without significantly increasing vector size.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional promoter/enhancer sequences are used to achieve liver-specific gene expression, then tissue specificity is improved, but vector size increases and cloning space is reduced
Solution Approach 1:
The patent extracts and utilizes specific liver-specific regulatory elements (enhancers) that can function independently or in combination with minimal promoters. By taking out the essential regulatory function from large traditional promoter sequences, the invention achieves liver-specificity while maintaining compact vector size. Examples include using the ApoE enhancer, Albumin enhancer, or other liver-specific enhancer sequences that can be inserted upstream of minimal promoters to confer tissue-specific expression without requiring large promoter sequences.
Solution Approach 2:
The patent segments the gene expression control system into separate functional modules: a minimal promoter (providing basal expression) and discrete liver-specific enhancer elements (providing tissue specificity). This segmentation allows independent optimization of each component and enables flexible combination of different enhancer-promoter pairs. The enhancer sequences (such as those from ApoE, Albumin, or HNF-1 binding sites) can be individually selected and combined with minimal promoters to achieve the desired balance between specificity and compactness.
2Productivity
If strong viral promoters like CMV or LTR are used, then expression levels are improved, but tissue specificity is lost
Solution Approach 1:
The patent applies local quality by placing liver-specific enhancer elements at specific locations (upstream of the minimal promoter) to confer tissue-specific regulatory control. The enhancer sequences contain binding sites for liver-specific transcription factors (such as HNF-1, C/EBP, FoxA1, RFX) that are selectively activated in hepatocytes. This localized placement of specificity-determining elements allows the system to achieve both high expression levels (through the strength of the enhancer-promoter interaction) and tissue specificity (through the liver-specific transcription factor binding sites).
Solution Approach 2:
The patent creates composite regulatory systems by combining minimal promoters with liver-specific enhancer sequences. These composite elements integrate the basal transcriptional activity of the minimal promoter with the tissue-specific regulatory control of the enhancer. The resulting hybrid regulatory cassette achieves both high expression levels and liver-specificity, overcoming the limitations of using either strong viral promoters (which lack specificity) or large traditional promoters (which reduce vector capacity).
3Productivity
If large promoter sequences are used to ensure sufficient expression, then expression levels are improved, but vector efficiency and cloning space are reduced
Solution Approach 1:
The patent extracts the essential liver-specific regulatory function from large traditional promoter sequences by identifying and utilizing specific enhancer elements. These compact enhancer sequences (ranging from approximately 50 to 500 base pairs) contain the critical transcription factor binding sites needed for liver-specific expression. By using these extracted enhancer elements instead of large promoter sequences, the invention maintains sufficient expression levels while dramatically reducing the regulatory element size, thereby improving vector efficiency and available cloning space.
Solution Approach 2:
The patent changes the parameters of the regulatory system by transitioning from large promoter sequences to compact enhancer-minimal promoter combinations. This parameter change involves selecting enhancer sequences with optimal strength and specificity characteristics, and pairing them with minimal promoters of appropriate basal activity. The result is a regulatory system that achieves the necessary expression levels with significantly reduced sequence length, improving both vector efficiency and ease of manufacture.
Data Source
AI summary
Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.